Loading...
Loading...
By Sergio Arturo Lievano Madrigal - Thu, 10/08/2026 - 16:10
This week, Mexico’s SUS draws 73,000 applicants for 12,750 clinics, WHO tracks NCD rise, Mexico chairs PAHO’s committee, and China seeks to lead WHO.
https://mexicobusiness.news/tag/cofepris
More Health
By Sergio Arturo Lievano Madrigal - Mon, 10/05/2026 - 11:45
Deisseroth, Hegemann, and Nagel win the 2026 Nobel Prize in Medicine for optogenetics, a light-based method to study brain circuits.
By MBN Staff - Fri, 09/25/2026 - 12:39
Mexico collected 70t of empty pesticide containers in Baja California, as part of a national strategy to improve agricultural waste management.
By Sergio Arturo Lievano Madrigal - Thu, 09/24/2026 - 15:21
Birmex's medicine tender, a COFEPRIS-Anvisa reliance pathway, public hospital upgrades, and AI in drug research shaped this Week in Health.
By Sergio Arturo Lievano Madrigal - Wed, 09/23/2026 - 10:38
Mexico and Brazil advance a pathway letting COFEPRIS rely on Anvisa reviews to decide on drug registrations within 45 business days.
By Sergio Arturo Lievano Madrigal - Fri, 09/18/2026 - 10:25
Anthropic confirms a Bay Area wet lab for physical biology experiments as it expands AI-driven drug research, while it stays out of clinical trials.
By Sergio Arturo Lievano Madrigal - Thu, 09/17/2026 - 09:46
Mölnlycke's diabetic amputation data, COFEPRIS's Edomex deal, and hospital groups on scale define this week's Health coverage.
By Sergio Arturo Lievano Madrigal - Tue, 09/15/2026 - 11:40
COFEPRIS and the State of Mexico sign a MX$6.76 million federal subsidy agreement for sanitary surveillance.
By Eliza Galeana - Fri, 09/11/2026 - 14:30
The Supreme Court authorized recreational cannabis self-consumption in food preparations.
By Sergio Arturo Lievano Madrigal - Fri, 09/11/2026 - 11:54
Mölnlycke says 85% of diabetic amputations in Mexico start with unhealed foot ulcers, spotlighting gaps in early wound care intervention.
By Sergio Arturo Lievano Madrigal - Thu, 09/10/2026 - 14:37
MHS 2026 spotlights digital health, chronic disease, and affordability, as pharma investment grows and COFEPRIS advances regulatory reform.
